57°

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
News
- Local News
- State News
Sports
- Local Sports
- Pro Sports
Lifestyle
- Local Entertainment
Multimedia
Community Choice
Features
Classifieds
- Place Ad
- Legal Notices
Public Notices
Obituaries
E-Edition
STOCKING STUFFER CONTEST

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

125.19 +3.72 (+3.07%)

Streaming Delayed Price Updated: 1:16 PM EST, Dec 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9

...

69 70 Next >

Visa, Disney, Blackstone And A Health Care Stock On CNBC's 'Final Trades' ↗

July 28, 2025

Visa, which will report third quarter results on Tuesday, July 29, is analyst Stephanie Link's final trade.

Via Benzinga

Why Gilead Sciences (GILD) Stock Is Up Today

July 25, 2025

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 3% in the afternoon session after its long-acting HIV prevention injection, lenacapavir, received a recommendation for approval...

Via StockStory

Topics Stocks World Trade

Why Gilead Sciences Stock Just Popped ↗

July 25, 2025

Gilead stock is flashing "buy" in bright green letters.

Via The Motley Fool

Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales ↗

July 25, 2025

Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, exceeding prior estimates.

Via Benzinga

Price Over Earnings Overview: Gilead Sciences ↗

July 25, 2025

Via Benzinga

This Gilead Sciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗

July 25, 2025

Via Benzinga

Gilead Gets Analyst Thumbs Up On Market Potential Of HIV-Prevention Injection, But Retail’s Not Ready To Cheer Yet ↗

July 25, 2025

Needham has a $133 price target on the stock, representing an upside of about 17.5% to the stock’s closing price on Thursday.

Via Stocktwits

Topics Workforce

Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention

July 25, 2025

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025

July 24, 2025

From Gilead Sciences, Inc.

Via Business Wire

1 Value Stock Worth Your Attention and 2 Facing Headwinds

July 24, 2025

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

Topics Supply Chain

Director Sells 11,136 Shares of SRRK, a Stock Up 330% in Past Year ↗

July 23, 2025

Via The Motley Fool

Topics Regulatory Compliance

Gilead Sciences, Omnicom Group, and QuinStreet Shares Skyrocket, What You Need To Know

July 23, 2025

A number of stocks jumped in the afternoon session after a new trade agreement between the United States and Japan spurred a broad market rally.

Via StockStory

Topics Stocks World Trade

NAFA Publishes New Fleet Safety Guidebook Aimed at Developing Safety-First Culture in all Organizations

July 23, 2025

Comtex News Network, Inc. is a content specialist offering actionable news distribution, global syndication, and traffic for your content

Via News Direct

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

July 23, 2025

From Pomerantz LLP

Via GlobeNewswire

2 Large-Cap Stocks to Consider Right Now and 1 That Underwhelm

July 21, 2025

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth...

Via StockStory

Topics Supply Chain

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

July 18, 2025

From Pomerantz LLP

Via GlobeNewswire

Expanding the Preventive Care Frontier: Dr. Reddy’s Launches Sanofi’s Beyfortus® in India

July 17, 2025

Via AB Newswire

Topics Death

Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics Segment

July 15, 2025

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Gilead Sciences (NASDAQ:GILD) and its peers.

Via StockStory

Topics Artificial Intelligence

Which S&P500 stocks are gapping on Tuesday? ↗

July 15, 2025

Wondering which stocks are making significant price gaps? Explore the S&P500 index on Tuesday to find the gap up and gap down stocks in today's session.

Via Chartmill

GILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law Firm

July 14, 2025

From The Schall Law Firm

Via Business Wire

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today ↗

July 14, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Gilead Sciences, Inc. - GILD

July 14, 2025

From Pomerantz LLP

Via GlobeNewswire

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025

July 14, 2025

From Gilead Sciences, Inc.

Via Business Wire

GILEAD SCIENCES INC (NASDAQ:GILD) – An Undervalued Biopharmaceutical Stock Worth Considering ↗

July 12, 2025

GILEAD SCIENCES INC (NASDAQ:GILD) appears undervalued with strong profitability and reasonable financial health, making it a potential candidate for value investors.

Via Chartmill

Bill Gates Warns Of 'Devestating Effects' Of USAID Funding Cuts: 'It's Not Too Late To Reverse Them' ↗

July 12, 2025

Bill Gates raises concerns over U.S. aid cuts' impact on HIV programs in Africa and calls for a reversal of the decision.

Via Benzinga

Guardant Health, Gilead Sciences, Inspire Medical Systems, Enovis, and AMN Healthcare Services Stocks Trade Down, What You Need To Know

July 11, 2025

A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada.

Via StockStory

Topics ETFs Stocks World Trade

Top S&P500 movers in Friday's session ↗

July 11, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

What's going on in today's session: S&P500 movers ↗

July 11, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.

Via Chartmill

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗

July 11, 2025

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.

Via Benzinga

Topics Government World Trade

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

July 10, 2025

From Pomerantz LLP

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

69 70 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Multimedia
Local Events
Classifieds
Obituaries
Weather
Online Features

Services

About Us
Contact Us
Promote Your Event
Subscriber Services
Online Forms
Rack Locations

woonsocketcall.com
Address: 154 Main Street
Woonsocket, RI 02895
Phone: 401-762-3000
Email: notices@woonsocketcall.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Gilead Sciences (NQ:GILD)

All News about Gilead Sciences

Sections

Services